BACKGROUND:Cognitive-behavioral therapy (CBT) consisting of exposure and response prevention (EX/RP) is efficacious as a treatment for obsessive-compulsive disorder (OCD). However, about half of patients have a partial or poor response to EX/RP treatment. This study examined potential predictors and moderators of CBT augmentation of pharmacotherapy, to identify variables associated with a poorer response to OCD treatment. METHOD: Data were drawn from a large randomized controlled trial that compared the augmenting effects of EX/RP to stress management training (SMT; an active CBT control) among 108 participants receiving a therapeutic dose of a serotonin reuptake inhibitor (SRI). Stepwise regression was used to determine the model specification. RESULTS: Pretreatment OCD severity and gender were significant moderators of outcome: severity affected SMT (but not EX/RP) outcome; and gender affected EX/RP (but not SMT) outcome. Adjusting for treatment type and pretreatment severity, significant predictors included greater co-morbidity, number of past SRI trials, and lower quality of life (QoL). Significant moderators, including their main-effects, and predictors accounted for 37.2% of the total variance in outcome, comparable to the impact of treatment type alone (R2=30.5%). These findings were replicated in the subgroup analysis of EX/RP alone (R2=55.2%). CONCLUSIONS: This is the first randomized controlled study to examine moderators and predictors of CBT augmentation of SRI pharmacotherapy. Although effect sizes for individual predictors tended to be small, their combined effect was comparable to that of treatment. Thus, future research should examine whether monitoring for a combination of these risk factors and targeting them with multi-modular strategies can improve EX/RP outcome.
RCT Entities:
BACKGROUND: Cognitive-behavioral therapy (CBT) consisting of exposure and response prevention (EX/RP) is efficacious as a treatment for obsessive-compulsive disorder (OCD). However, about half of patients have a partial or poor response to EX/RP treatment. This study examined potential predictors and moderators of CBT augmentation of pharmacotherapy, to identify variables associated with a poorer response to OCD treatment. METHOD: Data were drawn from a large randomized controlled trial that compared the augmenting effects of EX/RP to stress management training (SMT; an active CBT control) among 108 participants receiving a therapeutic dose of a serotonin reuptake inhibitor (SRI). Stepwise regression was used to determine the model specification. RESULTS: Pretreatment OCD severity and gender were significant moderators of outcome: severity affected SMT (but not EX/RP) outcome; and gender affected EX/RP (but not SMT) outcome. Adjusting for treatment type and pretreatment severity, significant predictors included greater co-morbidity, number of past SRI trials, and lower quality of life (QoL). Significant moderators, including their main-effects, and predictors accounted for 37.2% of the total variance in outcome, comparable to the impact of treatment type alone (R2=30.5%). These findings were replicated in the subgroup analysis of EX/RP alone (R2=55.2%). CONCLUSIONS: This is the first randomized controlled study to examine moderators and predictors of CBT augmentation of SRI pharmacotherapy. Although effect sizes for individual predictors tended to be small, their combined effect was comparable to that of treatment. Thus, future research should examine whether monitoring for a combination of these risk factors and targeting them with multi-modular strategies can improve EX/RP outcome.
Authors: Jonathan D Huppert; H Blair Simpson; Kore J Nissenson; Michael R Liebowitz; Edna B Foa Journal: Depress Anxiety Date: 2009 Impact factor: 6.505
Authors: Nienke H Tenneij; Harold J G M van Megen; Damiaan A J P Denys; Herman G M Westenberg Journal: J Clin Psychiatry Date: 2005-09 Impact factor: 4.384
Authors: Helen Blair Simpson; Jonathan D Huppert; Eva Petkova; Edna B Foa; Michael R Liebowitz Journal: J Clin Psychiatry Date: 2006-02 Impact factor: 4.384
Authors: J Cottraux; I Note; S N Yao; S Lafont; B Note; E Mollard; M Bouvard; A Sauteraud; M Bourgeois; J F Dartigues Journal: Psychother Psychosom Date: 2001 Nov-Dec Impact factor: 17.659
Authors: Beth S Gershuny; Lee Baer; Michael A Jenike; William E Minichiello; Sabine Wilhelm Journal: Am J Psychiatry Date: 2002-05 Impact factor: 18.112
Authors: Carlos Blanco; Mark Olfson; Dan J Stein; Helen Blair Simpson; Marc J Gameroff; William H Narrow Journal: J Clin Psychiatry Date: 2006-06 Impact factor: 4.384
Authors: Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu Journal: Am J Psychiatry Date: 2005-01 Impact factor: 18.112
Authors: Eric A Storch; Lisa J Merlo; Michael J Larson; Gary R Geffken; Heather D Lehmkuhl; Marni L Jacob; Tanya K Murphy; Wayne K Goodman Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-05 Impact factor: 8.829
Authors: Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Deborah Roth Ledley; Jonathan D Huppert; Shawn Cahill; Donna Vermes; Andrew B Schmidt; Elizabeth Hembree; Martin Franklin; Raphael Campeas; Chang-Gyu Hahn; Eva Petkova Journal: Am J Psychiatry Date: 2008-03-03 Impact factor: 18.112
Authors: Edna B Foa; Helen Blair Simpson; Michael R Liebowitz; Mark B Powers; David Rosenfield; Shawn P Cahill; Raphael Campeas; Martin Franklin; Chang-Gyu Hahn; Elizabeth A Hembree; Jonathan D Huppert; Andrew B Schmidt; Donna Vermes; Monnica T Williams Journal: J Clin Psychiatry Date: 2013-05 Impact factor: 4.384